Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia

The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the need for alternative or combinational therapies to achieve a mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovalovsky, Damian, Yoon, Jeong Heon, Cyr, Matthew G., Simon, Samantha, Voynova, Elisaveta, Rader, Christoph, Wiestner, Adrian, Alejo, Julie, Pittaluga, Stefania, Gress, Ronald E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384967/
https://www.ncbi.nlm.nih.gov/pubmed/33633313
http://dx.doi.org/10.1038/s41375-021-01188-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384967/
https://www.ncbi.nlm.nih.gov/pubmed/33633313
http://dx.doi.org/10.1038/s41375-021-01188-3

Ejemplares similares